Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid

WANG Qijun,RUAN Yue,GUO Fei,ZHU Haiqin,PAN Meng,Qijun Wang,Yue Ruan,Fei Guo,Haiqin Zhu,Meng Pan

DOI: https://doi.org/10.2340/actadv.v103.12324

2023-09-14

Abstract:Abstract is missing (Short communication)

dermatology

What problem does this paper attempt to address?

The Treatment of Refractory Atypical Bullous Pemphigoid with Generalized Eczema and Intense Pruritus with Dupilumab

Wei Li,Sheng Cai,Xiao‐Yong Man

DOI: https://doi.org/10.1111/dth.15243

2021-01-01

Dermatologic Therapy

Abstract:The data that support the findings of this study are available from the corresponding author upon reasonable request.
Evaluation of Dupilumab in Patients With Bullous Pemphigoid

Liuqi Zhao,Qijun Wang,Guirong Liang,Yuxi Zhou,Nam Yiu,Baoqi Yang,Guiying Zhang,Wei Li,Suying Feng,Panpan Shang,Xixue Chen,Xuejun Zhu,Jie Zheng,Meng Pan,Mingyue Wang

DOI: https://doi.org/10.1001/jamadermatol.2023.2428

IF: 11.816

2023-09-21

JAMA Dermatology

Abstract:This retrospective cohort study assesses the patient outcomes and safety of dupilumab in adults with bullous pemphigoid.

dermatology
Effectiveness Of Dupilumab For An Elderly Patient With Prurigo Nodularis Who Was Refractory And Contradicted To Traditional Therapy

Taoming Liu,Juan Bai,Su Wang,Shuni Ying,Sheng Li,Jianjun Qiao,Hong Fang

DOI: https://doi.org/10.2147/JAA.S300975

2021-01-01

Journal of Asthma and Allergy

Abstract:Prurigo nodularis (PN) is an intense pruritic skin condition. Treatment of PN is challenging. We described an elderly patient with PN who had contradictions of cyclosporine or methotrexate and achieved significant improvement after treatment with dupilumab. We also reviewed published cases of elderly patients with PN who were refractory to traditional therapy.
Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study

Dawei Huang,Yuexin Zhang,Yingyuan Yu,Yuxiong Jiang,Luyang Kong,Yangfeng Ding,Yuling Shi,Yunlu Gao

DOI: https://doi.org/10.1016/j.intimp.2023.111157

Abstract:Background: Bullous pemphigoid (BP) is a common subepidermal bullous disease. Dupilumab is a novel treatment for BP. However, its long-term efficacy and safety have not been demonstrated in prospective studies. Objective: Evaluate the long-term efficacy and safety of dupilumab in treating severe BP. Methods: Patients were divided into two groups: the methylprednisolone monotherapy group (M), and the methylprednisolone and dupilumab combination therapy group (D + M). This study consisted of two stages. The first stage focused on the initial treatment phase, where the early efficacy and safety was evaluated. The study then entered the 12-month maintenance treatment stage, where we assessed recurrence in both groups. Additionally, we evaluated the rate of healing of skin lesions, glucocorticoids burden and length of hospital stay and various laboratory test indicators. Results: After four weeks of treatment, the Bullous Pemphigoid Disease Area Index (BPDAI) and pruritus Numerical Rating Scale scores of the D + M group decreased significantly more than those of the M group. The median BPDAI at week 4 was 0 (range: 0.0-3.0) in the D + M group and 10.0 (5.0-12.0) in the M group (P < 0.001). Patients treated with dupilumab experienced a faster cessation of new blisters, quicker glucocorticoid reduction, shorter healing times, and shorter hospital stays (P < 0.001). Additionally, after two weeks of treatment, the levels of eosinophils and immunoglobulin E also decreased (P < 0.001). Follow-up studies further demonstrated that dupilumab monotherapy was associated with a lower recurrence rate. Notably, no serious adverse effects were observed in the study. Conclusions: Our study provides evidence for the efficacy of dupilumab in the treatment of BP based on prospective studies. Additionally, our findings suggest that dupilumab can be considered a reliable single-agent maintenance treatment due to its good safety profile and lower relapse.
Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study

Lingyu Hu,Ruiting Huang,Fuqiong Jiang,Shuqiong You,Qian Wu

DOI: https://doi.org/10.1002/iid3.924

Abstract:Objective: To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid. Methods: From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes. Results: The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0-3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment. Conclusion: Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.
Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter

Yihua Zhang,Jing Zhang,Jiawen Chen,Mengting Lin,Ting Gong,Bo Cheng,Chao Ji

DOI: https://doi.org/10.1111/ajd.13692

2021-08-26

Australasian Journal of Dermatology

Abstract:The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.

dermatology
Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study

赵柳琦,陈妍,陈丹阳,樊碧娆,王瑞,尚盼盼,陈喜雪,朱学骏,王明悦

DOI: https://doi.org/10.35541/cjd.20210813

2022-01-01

Chinese Journal of Dermatology

Abstract:Objective:To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid (BP) .Methods:Clinical data were collected from BP patients who received injections of dupilumab at an initial dose of 600 mg followed by an every-2-week regimen at a dose of 300 mg (the frequency of injections could be increased if necessary) in Department of Dermatology, Peking University First Hospital from October 2020 to October 2021, and their clinical manifestations and changes in laboratory indices were analyzed.Results:A total of 21 BP patients treated with dupilumab were included in this study. Nineteen (90.5%) patients achieved complete or marked disease control after 2-week treatment with dupilumab; 12 patients were followed up for 16 weeks, and all maintained complete disease control at 16 weeks. All patients had a bullous pemphigoid disease area index (BPDAI) score of 122.5 ± 51.1 points at baseline, which decreased to 30.6 ± 27.4 points after 2-week treatment with dupilumab ( t = 8.53, P < 0.001) , and continued to decrease to 12.7 ± 9.1 points after 4-week treatment ( t = 9.73, P < 0.001) . Pruritus was markedly relieved in all the 21 patients within 4-week treatment with dupilumab. Among 10 patients with elevated eosinophil counts at baseline, the eosinophil counts markedly decreased in 9 after treatment. The serum IgE level was elevated in 7 patients at baseline, which markedly decreased in 6 after treatment. Viral conjunctivitis occurred in 1 (4.8%) patient, and no adverse reactions were observed in other patients. Conclusion:Dupilumab is effective in the control of BP and relief of pruritus, with a favorable safety profile.
Belimumab for the Treatment of Pemphigus

Jiali Ruan,Xuetong Zhang,Min Zheng

DOI: https://doi.org/10.1111/dth.15621

2022-01-01

Dermatologic Therapy

Abstract:Dermatologic TherapyVolume 35, Issue 8 e15621 LETTER Belimumab for the treatment of pemphigus Jiali Ruan, Jiali Ruan orcid.org/0000-0003-0994-3518 Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorXuetong Zhang, Xuetong Zhang orcid.org/0000-0002-9226-8703 Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Corresponding Author Min Zheng minz@zju.edu.cn Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China Correspondence Min Zheng, Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China. Email: minz@zju.edu.cnSearch for more papers by this author Jiali Ruan, Jiali Ruan orcid.org/0000-0003-0994-3518 Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorXuetong Zhang, Xuetong Zhang orcid.org/0000-0002-9226-8703 Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Corresponding Author Min Zheng minz@zju.edu.cn Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China Correspondence Min Zheng, Dermatology Department, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China. Email: minz@zju.edu.cnSearch for more papers by this author First published: 07 June 2022 https://doi.org/10.1111/dth.15621 Jiali Ruan and Xuetong Zhang are joint first authors. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume35, Issue8August 2022e15621 RelatedInformation
A Systematic Evaluation of Dupilumab for Bullous Pemphigoid Treatment

Shengzhen Ye,Guihua Ling,Mingling Chen

DOI: https://doi.org/10.1155/2024/1171779

2024-04-27

Dermatologic Therapy

Abstract:This paper systematically reviews the current articles regarding the use of dupilumab in the treatment of bullous pemphigoid (BP) to evaluate its safety and efficacy. PubMed, Embase, Cochrane Library, and Web of Science databases were searched for publications on dupilumab for BP from inception to 10 March, 2023. A total of 26 studies were included for systematic review. The primary outcome was clinical remission, and the secondary outcomes were recurrence and adverse events. Among 96 patients, 71.8% (n = 69/96) received systemic or topical steroids, immunosuppressants, immunomodulators, intravenous immunoglobulins, antihistamines, plasmapheresis, rituximab, and omalizumab, but none of them were successful. After dupilumab treatment, 66.7% (n = 64/96) of patients achieved complete remission, 25.0% (n = 24/96) had partial remission, 5.2% (n = 5/96) showed no remission, and no patients experienced deterioration. In addition, 1.0% (n = 1/96) and 2.0% (n = 2/96) patients stopped using dupilumab due to adverse reactions and cost, respectively. The average remission time was 4.5 months. 46.2% (n = 25/96) of the patients were followed up with a median follow-up of 8 months and only 2 patients relapsed at 8 and 7 months, respectively. Adverse event was 16.9% (n = 12/71), of which transient eosinophilia was the most common. This study indicates that the dupilumab is a promising treatment for BP with high clinical benefit associated with low recurrence rate, adverse event rate, and mortality. However, a large-scale randomized controlled trial is needed to further confirm the safety and efficacy of dupilumab in patients with BP treatment.

dermatology
Use of dupilumab for recalcitrant bullous pemphigoid: A case report

Jillian Lamb,Kerri Purdy,Ashley Sutherland

DOI: https://doi.org/10.1177/2050313X241274855

2024-08-22

Abstract:Bullous pemphigoid is an autoimmune blistering disease affecting the dermo-epidermal junction, most commonly seen in older patients. First-line treatment includes systemic, topical corticosteroids and/or steroid-sparing immunosuppressants. Treatment with these medications may be limited by their safety profile. Dupilumab is a humanized monoclonal antibody targeting interleukin-4 and interleukin-13 cytokines currently indicated for moderate-to-severe atopic dermatitis, severe asthma, chronic rhinosinusitis with nasal polyposis, and moderate-to-severe prurigo nodularis. We report a case of a patient with recalcitrant bullous pemphigoid effectively treated with dupilumab.
Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy

Po-Ta Lai,Han-Chi Tseng

DOI: https://doi.org/10.4103/1027-8117.357999

2022-12-28

Dermatologica Sinica

Abstract:Po-Ta Lai, Han-Chi Tseng Dermatologica Sinica 2022 40(4):237-238

dermatology
Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

Maleck Saleh,Matthew Reedy,Helen Torok,Joshua Weaver

2021-04-15

Abstract:Bullous pemphigoid is an autoimmune skin disease that results in formation of pruritic blisters. Most cases are treated with a combination of systemic and topical corticosteroids as well as other immunomodulatory drugs. Dupilumab is a fully human monoclonal antibody that acts as an antagonist against IL4Ra traditionally used in the treatment of atopic dermatitis. We present an 80-year-old man with moderate to severe bullous pemphigoid successfully treated with dupilumab.
A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis

Siji Chen,Shaowei Zhan,Chunting Hua,Yi Tang,Hao Cheng

DOI: https://doi.org/10.3389/fimmu.2022.825796

2022-02-09

Abstract:Background: Pemphigus vulgaris (PV) is a kind of IgG-mediated autoimmune blistering disease (AIBD) that is characterized by loss of keratinocyte adhesion in the epithelium of mucous membranes or skin. Recently, pemphigus vulgaris was thought to be associated with classical T helper 2 (TH2)-type cytokines such as interleukin-4 (IL-4) and interleukin-17 (IL-17) signaling pathway. A humanized monoclonal IgG4 antibody called dupilumab binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα) and inhibits the signaling of IL-4 and interleukin-13 (IL-13), which has been successfully applied for atopic dermatitis and asthma. Currently, the clinical trial evaluating dupilumab in bullous pemphigoid is ongoing. Objective: To determine whether dupilumab may be of benefit in the aggressive refractory pemphigus vulgaris. Methods: We report a 35-year old male with refractory pemphigus vulgaris and pulmonary tuberculosis who received treatment with dupilumab for 10 weeks. The mRNA expression of peripheral blood mononuclear cells (PBMCs) was analyzed by RNA sequencing (RNA-seq) which showed the gene expression changes after treatment. Results: The skin lesions of the patient improved in response to the combined use of dupilumab, moderate dose of glucocorticosteroids, and intravenous immune globulin (IVIG). Downregulations of inflammatory response-related genes and IL-17 signaling pathway-related genes were observed in PBMCs. Conclusion: We describe a patient with refractory pemphigus vulgaris and pulmonary tuberculosis who had the disease under control with combined use of dupilumab as an add-on treatment. Dupilumab may provide a beneficial effect in aggressive refractory pemphigus vulgaris.
Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients

Austinn C Miller,Laurie A Temiz,Susuana Adjei,Miguel A Duran,Jeffrey Sassmannshausen,Arturo Dominguez,Cristina Thomas,Jimmy D Schmidt,Michael Bernhardt,Coley J Doolittle-Amieva,Ata S Moshiri,Anthony J Thompson,Penelope Pyoung Kim-Lim,Alexzandra V Mattia,Stephen K Tyring

DOI: https://doi.org/10.36849/JDD.8258

2024-06-01

Abstract:Bullous pemphigoid is often difficult to treat with the limited therapies available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. We performed a multicenter, retrospective case series between March 2020 to August 2022. Patients received a loading dose of dupilumab 600 mg, followed by 300 mg maintenance dose with varying administration frequency tailored to individual patient response. All patients experienced at least some improvement in blister formation and pruritus, with 23 (76.7%) of patients demonstrating either complete clearance of blistering or marked response. Complete clearance of pruritus or marked response was noted in 25 (83.3%) of patients. Eight patients were effectively maintained solely on dupilumab. One (3.3%) patient reported an injection site reaction. Thirty patients represent a small sample, however, to our knowledge, this is the second largest group of BP treated with dupilumab. Furthermore, we provide an understandable framework for clinicians outside of academics to follow and assess treatment responses in their BP patients treated with dupilumab. Dupilumab should be considered as a therapeutic option in patients with bullous pemphigoid given its ability to induce sustained blistering and pruritus response in both typical and refractory cases while maintaining a favorable safety profile. J Drugs Dermatol. 2024;23(6):e144-e148. doi:10.36849/JDD.8258e.
Rituximab in combination with corticosteroid in the treatment of 14 patients with refractory bullous diseases

Yu-fang QIU,Shan ZHONG,Pei-ru WANG,Xue-jun ZHU,Xi-xue CHEN

DOI: https://doi.org/10.3969/j.issn.1000-4963.2011.09.008

2011-01-01

Abstract:Objective: To assess the efficacy and safety of rituximab in the treatment of refractory bullous diseases. Methods: Fourteen patients (8 PV, 3 BP, 2 EBA and 1 PE) with refractory bullous disease were treated with four weekly infusions of 375 mg of rituximab per square meter of body-surface area in combination with corticosteroid. Routine examination of blood and urine, liver and renal function, blood lipids, blood glucose, electrolytes, immunoglobulin, specific antibodies of bullous diseases and peripheral blood B- and T-lymphocyte subpopulations were examined before treatment, during treatment and after treatment. Results: Eleven of the 14 patients had a complete remission and three had a partial remission. Of the eleven patients who had a complete remission, two patients had a relapse 9 and 8 months after treatment respectively; one patient died of pneumonia 3 months after treatment; the remainder's condition was stable, two of them stop any therapy now. Three of partial remission patients were not receiving any drug and new rashes only occurred after scratching. Conclusions: Rituximab is an effective and safe treatment for refractory bullous diseases. Larger series with a longer follow-up are needed to assess the long-term effects and risks of this treatment.
Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid

Jin Yang,Haiqing Gao,Zhen Zhang,Chang Tang,Zihua Chen,Lanting Wang,Fanping Yang,Shengan Chen,Shan He,Shutao Liu,Lin Tang,Yu Xu,Yao Hu,Li Ma,Ying Zhao,Xiaoqun Luo

DOI: https://doi.org/10.1111/dth.15648

2022-01-01

Dermatologic Therapy

Abstract:Routine systemic therapy for bullous pemphigoid (BP) has been challenged due to the inevitably adverse effects. According to the successful applications of dupilumab in BP cases reported, therefore, we investigate the real-life efficacy and safety of dupilumab combined with low-dose oral steroid for BP. A cohort of BP patients who received either dupilumab plus low-dose methylprednisolone (dupilumab group) or merely methylprednisolone (control group) was retrospectively reviewed. The time to disease control was investigated. Additionally, the control dose and cumulative dosage of steroids, Bullous Pemphigoid Disease Area Index (BPDAI) scores, pruritus scores, and adverse events were assessed. A total of 40 patients, with 20 in each group, were retrospectively studied. The time to disease control was shorter in the dupilumab group than the control group (14 days vs. 19 days, p = 0.043). When the disease was controlled, the control dose and cumulative dosage of methylprednisolone in the dupilumab group were substantially lower than those of the control (24.6 mg vs. 48.8 mg, 376.8 mg vs. 985.6 mg, both p < 0.01). Compared with the control, the percentage change from baseline in BPDAI scores and pruritus scores were both significantly reduced, and the adverse events were also less frequent in the dupilumab group. The combination therapy of dupilumab plus low-dose methylprednisolone exhibits superior efficacy and safety in comparison with the current first-line systemic therapy for BP.
Successful Treatment of Secukinumab-Resistant Palmoplantar Pustulosis by Dupilumab: A Case Report.

Yu-Xin Zheng,Min Zheng,Sui-Qing Cai

DOI: https://doi.org/10.1111/dth.15781

2022-01-01

Dermatologic Therapy

Abstract:Dermatologic TherapyVolume 35, Issue 11 e15781 LETTER Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author Yu-Xin Zheng, Yu-Xin Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorMin Zheng, Min Zheng Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorSui-Qing Cai, Corresponding Author Sui-Qing Cai [email protected] Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence Sui-Qing Cai, Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Email: [email protected]Search for more papers by this author First published: 20 August 2022 https://doi.org/10.1111/dth.15781 Funding information: This study was funded by the grant from the National Natural Science Foundation of China (NFSC) (82073426). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: recent advances in Etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020; 21(3): 355-370. 2Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086): 2287-2303. 3Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019; 80(5): 1344-1352. 4Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(7):e574-e576. 5Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2021; 86(3): 708-709. 6Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like eruption triggered by Dupilumab therapy. Dermatitis. 2021; 32(6): e147-e148. 7Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019; 44(3): e49-e50. 8McCluskey D, Benzian-Olsson N, Mahil SK, et al. Single-cell analysis implicates Th17 to Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;S0091-6749(22)00624-8. Volume35, Issue11November 2022e15781 ReferencesRelatedInformation
Long-term Remission of Severe and Refractory Chronic Actinic Dermatosis with Dupilumab: A Case Report with Review of the Literature

Clélia Vanhaecke,Manuelle Viguier

DOI: https://doi.org/10.2340/actadv.v104.40453

2024-08-23

Abstract:Abstract is missing (Short communication)

dermatology
Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study

Si-Hang Wang,Ying Shan,Si-Zhe Li,Ya-Gang Zuo

DOI: https://doi.org/10.3389/fimmu.2023.1165106

IF: 7.3

2023-07-20

Frontiers in Immunology

Abstract:Background Bullous pemphigoid (BP) is a common subepidermal bullous disorder that lacks adequate treatment alternatives. Dupilumab, an anti-interleukin (IL) 4 receptor α antibody blocking Th2 molecules IL-4 and 13, has been used off-label and shown to be effective in refractory BP cases. Methods BP patients with various disease severities and comorbidities were included in this case series. All patients received dupilumab alone or in combination with immunosuppressants in a real-world setting. Complete remission (CR) was defined as the absence of pruritus symptoms and previous BP eruptions, with only hyperpigmentation patches and without newly occurring lesions for at least 4 weeks. Disease relapse was classified as the appearance of three or more new lesions within 1 month or at least one large urticarial or eczematous lesion that did not resolve within a week. Findings Ten individuals were enrolled in this case series. Pruritus symptoms and BP eruptions improved significantly in nine patients (90%). Seven patients (70%) attained CR, including all mild-to-moderate (100%) cases and three of six (50%) severe BP cases. At the dupilumab monotherapy stage, eosinophilia was observed in two severe cases. One patient out of seven (14.3%) relapsed after 1 year of follow-up after CR. Conclusion Treatment of BP with diverse comorbidities with anti-IL-4 receptor α antibody provides further credentials to a prospective randomized study. More impressive efficacy and safety profiles were observed in patients with mild-to-moderate disease after 1 year of follow-up. Eosinophilia may occur in patients receiving dupilumab monotherapy.

immunology
Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types

Tianmeng Yan,Yinghan Xie,Yuhua Liu,Ying Shan,Xiaoyan Wu,Jing Wang,Ya-Gang Zuo,Zhenying Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1194088

2023-07-27

Abstract:Background: Bullous pemphigoid (BP) is an autoimmune skin-blistering disease. Systemic corticosteroids remain the first line treatment for moderate-to-severe BP with the potential for severe adverse events. Dupilumab has emerged as an alternative option for BP patients. Objective: We evaluated the efficiency and safety of dupilumab on BP treatment and explored a mode of drug action in depth. Methods and results: A multicenter retrospective cohort included 20 BP patients who received dupilumab with or without systemic corticosteroid in dupilumab group, and 20 matched BP patients who received corticosteroid alone in conventional group. Serum samples were collected from 20 patients (10 from dupilumab group and 10 from conventional group) at baseline and week 4. Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. However, dupilumab did not decrease BP180 antibody despite an obvious clinical improvement. Comparative plasma proteomic analysis performed before and after treatment in 3 BP patients from dupilumab group revealed that drug use was associated with 30 differentially expressed proteins, including 26 down-regulated and 4 up-regulated proteins. The former consisted of immune related proteins involved in T/B cell interactions (inducible T-cell co-stimulator ligand, ICOSL) and in the activation of eosinophils (PRG2), mast cells (S100A12), and complement (CR2). TARC and ICOSL levels correlated with BP severity in patients who received either dupilumab or conventional treatment. Conclusion: Dupilumab has similar efficacy in treating BP as conventional drugs, by inhibiting the activities of many types of immune cells and complement, and regulating the interactions between T and B cells.

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid

The Treatment of Refractory Atypical Bullous Pemphigoid with Generalized Eczema and Intense Pruritus with Dupilumab

Evaluation of Dupilumab in Patients With Bullous Pemphigoid

Effectiveness Of Dupilumab For An Elderly Patient With Prurigo Nodularis Who Was Refractory And Contradicted To Traditional Therapy

Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study

Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study

Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter

Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study

Belimumab for the Treatment of Pemphigus

A Systematic Evaluation of Dupilumab for Bullous Pemphigoid Treatment

Use of dupilumab for recalcitrant bullous pemphigoid: A case report

Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy

Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis

Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients

Rituximab in combination with corticosteroid in the treatment of 14 patients with refractory bullous diseases

Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid

Successful Treatment of Secukinumab-Resistant Palmoplantar Pustulosis by Dupilumab: A Case Report.

Long-term Remission of Severe and Refractory Chronic Actinic Dermatosis with Dupilumab: A Case Report with Review of the Literature

Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study

Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types